Pharmaceuticals

"Pharmaceuticals" Main

Latest Morning Briefing Stories

KHN’s ‘What the Health?’: Election Preview: What’s Next for Health?

KFF Health News Original

How will health issues affect voter choices? What will happen if President Donald Trump is reelected or the White House goes to Joe Biden? In this special election preview episode, Margot Sanger-Katz of The New York Times, Joanne Kenen of Politico and Rebecca Adams of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more.

New Laws Keep Pandemic-Weary California at Forefront of Health Policy Innovation

KFF Health News Original

Gov. Gavin Newsom approved many consequential health care bills by his bill-signing deadline Wednesday, including a ban on the sale of menthol and other flavored tobacco products, the creation of a state generic drug label and better coverage for mental health disorders.

Sky-High Drug Prices Driven by Pharma Profits, House Dems Charge

KFF Health News Original

Democrats on the House Oversight Committee released a damning investigation Wednesday of drug company pricing tactics and profits, as two days of hearings with testimony from pharmaceutical industry CEOs begin.

Trump Approves Final Plan to Import Drugs From Canada ‘for a Fraction of the Price’

KFF Health News Original

The announcement clears the way for Florida and other states to implement a program bringing medications across the border to save money. The effort is strongly opposed by drugmakers and the Canadian government.

KHN’s ‘What the Health?’: ACA in Peril With Ginsburg’s Seat in Play

KFF Health News Original

The death of Supreme Court Justice Ruth Bader Ginsburg is giving new life to the latest constitutional challenge to the Affordable Care Act. It also places anti-abortion activists on the cusp of a court majority large enough to ensure the rollback of the right to abortion and, possibly, some types of birth control. Meanwhile, Health and Human Services Secretary Alex Azar tries to centralize power at the sprawling department plagued by miscommunications and scandals. Anna Edney of Bloomberg News, Kimberly Leonard of Business Insider and Mary Ellen McIntire of CQ Roll Call join KHN’s Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHN’s Sarah Jane Tribble about her new podcast, “Where It Hurts,” debuting Sept. 29.

These Secret Safety Panels Will Pick the COVID Vaccine Winners

KFF Health News Original

Data and safety monitoring boards work under a cloak of secrecy meant to prevent undue influence by stakeholders, such as companies or the government. In the Trump era, some worry the anonymity could actually invite it.

It’s Not Just Insulin: Lawmakers Focus on Price of One Drug, While Others Rise Too

KFF Health News Original

While insulin is the poster child for outrageous prescription costs, patients are paying ever more to treat depression, asthma, HIV, cholesterol and more. And the pandemic has overtaken efforts to force the issue in Congress.

Signs of an ‘October Vaccine Surprise’ Alarm Career Scientists

KFF Health News Original

President Donald Trump has the legal power to authorize a COVID vaccine over the objections of the Food and Drug Administration and vaccine manufacturers. Such a move could further erode public trust in a vaccine and foist an unsafe shot on Americans.

Election Gift for Florida? Trump Poised to Approve Drug Imports From Canada

KFF Health News Original

The Trump administration is primed to approve a plan designed to help lower costs of some prescription drugs by allowing states to import them from Canada. The announcement could come before Election Day, and Florida appears to be in line to go first.

KHN’s ‘What the Health?’: It’s Scandal Week

KFF Health News Original

President Donald Trump this week issued a prescription drug pricing order unlikely to lower drug prices, and he contradicted comments by his director of the Centers for Disease Control and Prevention on the need for mask-wearing and predictions for vaccine availability. Meanwhile, scandals erupted at the CDC, the Centers for Medicare & Medicaid Services and the Food and Drug Administration. And the number of people without health insurance grew in 2019, reported the Census Bureau, even while the economy soared. Alice Miranda Ollstein of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss this and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

COVID Vaccine Trials Move at Warp Speed, But Recruiting Black Volunteers Takes Time

KFF Health News Original

The National Institutes of Health has suggested minorities should be overrepresented in COVID-19 vaccine trials — perhaps at rates that are double their percentage of the U.S. population. But efforts to recruit patients from racial minority groups are just beginning, while some trials have already advanced to phase 3.

NIH ‘Very Concerned’ About Serious Side Effect in Coronavirus Vaccine Trial

KFF Health News Original

The AstraZeneca trial is on hold in the U.S. as scientists try to unravel whether a rare neurological condition is linked to the vaccine. But regulators are frustrated by a lack of information from the drugmaker.

California Rx: State May Dive Into Generic Drug Market

KFF Health News Original

California could become the first state to develop its own line of generic drugs under a bill approved Monday by the legislature. The measure heads to Gov. Gavin Newsom for consideration.